^
Association details:
| Biomarker: | SLFN11 expression |
|---|---|
| Cancer: | Esophageal Squamous Cell Carcinoma |
| Drug: | cisplatin (DNA synthesis inhibitor) + 5-fluorouracil (Thymidylate synthase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1712P - Usefulness of schlafen-11 expression level in cstage II/III esophageal squamous cell carcinoma
Published date:
09/05/2022
Excerpt:
We retrospectively evaluated pts with ESCC who received NAC-FP...3-year OS rate was 71.0% in P, 14.6% in N, respectively (HR 0.22 [95%CI: 0.08-0.57], p<0.01). According to cstage II, 3-year DFS rate was 85.7% vs 0.0%, respectively (HR 0.16 [95%CI: 0.02-1.03], p=0.03). 3-year OS rate was 85.7% vs 26.7%, respectively (HR 0.09 [95%CI: 0.02-0.52], p<0.01)...It was estimated that the SLFN-11 expression level could be useful as one of the possible predictive and prognostic markers in ESCC.
